Literature DB >> 10869453

Extrapolation of a PBPK model for dioxins across dosage regimen, gender, strain, and species.

X Wang1, M J Santostefano, M J DeVito, L S Birnbaum.   

Abstract

A physiologically based pharmacodynamic (PBPK) model for 2,3,7, 8-tetrachlorodibenzo-p-dioxin (TCDD) was developed based on pharmacokinetic data from acute oral exposures of TCDD to female Sprague-Dawley rats (Wang et al., 1997, Toxicol Appl. Pharmacol 147, 151-168). In the present study, the utility of this model to predict the disposition of TCDD in male and female Sprague-Dawley and female Wistar rats exposed to TCDD through different dosage regimens was examined. The ability of the model to predict the disposition of 2-iodo-3,7,8-trichlorodibenzo-p-dioxin (ITrCDD) in mice (Leung, et al., 1990, Toxicol. Appl. Pharmacol. 103, 399-410) was also examined. The ability of the model to predict across routes of exposure was assessed with intravenous injection data (5.6 microg/kg bw) (Li et al., 1995, Fundam. Appl. Toxicol. 27, 70-76) in female rats. Analysis across gender extrapolations used data for male Sprague-Dawley rats exposed intravenously to 9.25 microg TCDD/kg bw (Weber et al., 1993, Fundam. Appl. Toxicol. 21, 523-534). The analysis of across-dosage regimen and stains of rats extrapolations were assessed using data from rats exposed to TCDD through a loading/maintenance dosage regimen (Krowke et al., 1989, Arch. Toxicol. 63, 356-360). The physiological differences between gender, strain, and species were taken into account when fitting the PBPK model to these data sets. The results demonstrate that the PBPK model for TCDD developed for female Sprague-Dawley rats exposed by acute oral dosing accurately predicts the disposition of TCDD, for different gender and strain of rats across varying dosage regimens, as well as in a strain of mice. Minimal changes in fitted parameters were required to provide accurate predictions of these data sets. This study provides further confirmation of the potential use of physiological modeling in understanding pharmacokinetics and pharmacodynamics.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869453     DOI: 10.1093/toxsci/56.1.49

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  5 in total

Review 1.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Inflammatory pathway genes belong to major targets of persistent organic pollutants in adipose cells.

Authors:  Min Ji Kim; Véronique Pelloux; Erwan Guyot; Joan Tordjman; Linh-Chi Bui; Aline Chevallier; Claude Forest; Chantal Benelli; Karine Clément; Robert Barouki
Journal:  Environ Health Perspect       Date:  2012-01-19       Impact factor: 9.031

3.  Use of a physiologically based pharmacokinetic model for rats to study the influence of body fat mass and induction of CYP1A2 on the pharmacokinetics of TCDD.

Authors:  Claude Emond; Linda S Birnbaum; Michael J DeVito
Journal:  Environ Health Perspect       Date:  2006-09       Impact factor: 9.031

4.  Highlight report: Interspecies extrapolation by physiologically based pharmacokinetic modeling.

Authors:  Agata Widera
Journal:  EXCLI J       Date:  2015-09-01       Impact factor: 4.068

5.  Streamlining physiologically-based pharmacokinetic model design for intravenous delivery of nanoparticle drugs.

Authors:  Anh-Dung Le; Helen J Wearing; Dingsheng Li
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-02-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.